CHA Biotech (KOSDAQ:A085660) - Share price, News & Analysis

A085660 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

A085660 Stock Overview

CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services.

Risk Analysis

Earnings have declined by 4.3% per year over past 5 years

Shareholders have been diluted in the past year

CHA Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CHA Biotech
Historical stock prices
Current Share Price	₩17,400.00
52 Week High	₩31,100.00
52 Week Low	₩15,500.00
Beta	1.03
1 Month Change	-6.45%
3 Month Change	4.82%
1 Year Change	-9.14%
3 Year Change	6.75%
5 Year Change	39.76%
Change since IPO	133.13%

Recent News & Updates

Mar 01

Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Jan 25

If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

CHA Biotech Co., Ltd. ( KOSDAQ:085660 ) shareholders should be happy to see the share price up 19% in the last quarter...

Shareholder Returns

	A085660	KR Healthcare	KR Market
7D	0%	7.5%	1.6%
1Y	-9.1%	-39.9%	-14.2%

Return vs Industry: A085660 exceeded the KR Healthcare industry which returned -39.9% over the past year.

Return vs Market: A085660 exceeded the KR Market which returned -14.2% over the past year.

Price Volatility

Is A085660's price volatile compared to industry and market?
A085660 volatility
A085660 Average Weekly Movement	4.5%
Healthcare Industry Average Movement	5.8%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A085660 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A085660's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	205	n/a	https://www.chabio.com

CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.

CHA Biotech Fundamentals Summary

How do CHA Biotech's earnings and revenue compare to its market cap?
A085660 fundamental statistics
Market Cap	₩979.07b
Earnings (TTM)	-₩21.37b
Revenue (TTM)	₩747.67b

1.3x

P/S Ratio

-45.8x

P/E Ratio

Is A085660 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A085660 income statement (TTM)
Revenue	₩747.67b
Cost of Revenue	₩534.15b
Gross Profit	₩213.51b
Other Expenses	₩234.88b
Earnings	-₩21.37b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-379.72
Gross Margin	28.56%
Net Profit Margin	-2.86%
Debt/Equity Ratio	41.6%

How did A085660 perform over the long term?

See historical performance and comparison

Valuation

Is CHA Biotech undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

2.11x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A085660 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.

PE vs Market: A085660 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A085660's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A085660 is good value based on its PB Ratio (2.1x) compared to the KR Healthcare industry average (2.3x).

Future Growth

How is CHA Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

16.6%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CHA Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has CHA Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-4.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A085660 is currently unprofitable.

Growing Profit Margin: A085660 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A085660 is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare A085660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A085660 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.2%).

Return on Equity

High ROE: A085660 has a negative Return on Equity (-4.21%), as it is currently unprofitable.

Financial Health

How is CHA Biotech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A085660's short term assets (₩577.5B) exceed its short term liabilities (₩414.7B).

Long Term Liabilities: A085660's short term assets (₩577.5B) exceed its long term liabilities (₩354.3B).

Debt to Equity History and Analysis

Debt Level: A085660 has more cash than its total debt.

Reducing Debt: A085660's debt to equity ratio has increased from 27.5% to 41.6% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A085660 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A085660 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 37% each year.

Dividend

What is CHA Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A085660's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A085660's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A085660's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A085660's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A085660 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

CHA Biotech has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31